New Releases from NCBI BookshelfDurvalumab (Imfinzi): Indication: As monotherapy, for the treatment of adult patients with limited-stage small cell lung cancer whose disease has not progressed following platinum-based chemoradiation therapy: Reimbursement Recommendation [Internet].​Durvalumab (Imfinzi): Indication: As monotherapy, for the treatment of adult patients with limited-stage small cell lung cancer whose disease has not progressed following platinum-based chemoradiation therapy: Reimbursement Recommendation [Internet].